113 related articles for article (PubMed ID: 23826879)
1. Biopharmaceutical characterization, metabolism, and brain penetration of the triple reuptake inhibitor amitifadine.
Bymaster FP; Chao P; Schulze H; Tran PV; Marshall RD
Drug Metab Lett; 2013 Mar; 7(1):23-33. PubMed ID: 23826879
[TBL] [Abstract][Full Text] [Related]
2. Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity.
Golembiowska K; Kowalska M; Bymaster FP
Synapse; 2012 May; 66(5):435-44. PubMed ID: 22213370
[TBL] [Abstract][Full Text] [Related]
3. Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder.
Xue W; Wang P; Tu G; Yang F; Zheng G; Li X; Li X; Chen Y; Yao X; Zhu F
Phys Chem Chem Phys; 2018 Feb; 20(9):6606-6616. PubMed ID: 29451287
[TBL] [Abstract][Full Text] [Related]
4. The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: a microdialysis study in olfactory bulbectomized rats.
Prins J; Westphal KG; Korte-Bouws GA; Quinton MS; Schreiber R; Olivier B; Korte SM
Pharmacol Biochem Behav; 2011 Jan; 97(3):444-52. PubMed ID: 20934452
[TBL] [Abstract][Full Text] [Related]
5. In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human.
Erickson DA; Hollfelder S; Tenge J; Gohdes M; Burkhardt JJ; Krieter PA
Drug Metab Dispos; 2007 Dec; 35(12):2232-41. PubMed ID: 17881661
[TBL] [Abstract][Full Text] [Related]
6. Prolonging the Reduction of Nicotine Self-Administration in Rats by Coadministering Chronic Nicotine With Amitifadine, a Triple Monoamine Reuptake Inhibitor With CYP2B6 Inhibitory Actions.
Levin ED; Wells C; Slade S; Lee M; McKinney AA; Rose JE; Rezvani AH
Nicotine Tob Res; 2020 Feb; 22(2):232-237. PubMed ID: 31187118
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Tran P; Skolnick P; Czobor P; Huang NY; Bradshaw M; McKinney A; Fava M
J Psychiatr Res; 2012 Jan; 46(1):64-71. PubMed ID: 21925682
[TBL] [Abstract][Full Text] [Related]
8. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.
Kalgutkar AS; Tugnait M; Zhu T; Kimoto E; Miao Z; Mascitti V; Yang X; Tan B; Walsky RL; Chupka J; Feng B; Robinson RP
Drug Metab Dispos; 2011 Sep; 39(9):1609-19. PubMed ID: 21690265
[TBL] [Abstract][Full Text] [Related]
9. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
Hyland R; Roe EG; Jones BC; Smith DA
Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.
Gerber JG; Rhodes RJ; Gal J
Chirality; 2004 Jan; 16(1):36-44. PubMed ID: 14628297
[TBL] [Abstract][Full Text] [Related]
11. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.
Jiang R; Yamaori S; Takeda S; Yamamoto I; Watanabe K
Life Sci; 2011 Aug; 89(5-6):165-70. PubMed ID: 21704641
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
[TBL] [Abstract][Full Text] [Related]
13. Human cytochrome P450-catalyzed conversion of the proestrogenic pesticide methoxychlor into an estrogen. Role of CYP2C19 and CYP1A2 in O-demethylation.
Stresser DM; Kupfer D
Drug Metab Dispos; 1998 Sep; 26(9):868-74. PubMed ID: 9733665
[TBL] [Abstract][Full Text] [Related]
14. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
[TBL] [Abstract][Full Text] [Related]
15. DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile.
Beer B; Stark J; Krieter P; Czobor P; Beer G; Lippa A; Skolnick P
J Clin Pharmacol; 2004 Dec; 44(12):1360-7. PubMed ID: 15545306
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.
Mössner LD; Schmitz A; Theurillat R; Thormann W; Mevissen M
Am J Vet Res; 2011 Nov; 72(11):1505-13. PubMed ID: 22023129
[TBL] [Abstract][Full Text] [Related]
17. Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats.
Miller LL; Leitl MD; Banks ML; Blough BE; Negus SS
Pain; 2015 Jan; 156(1):175-184. PubMed ID: 25599313
[TBL] [Abstract][Full Text] [Related]
18. Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats.
Levin ED; Wells C; Johnson JE; Rezvani AH; Bymaster FP; Rose JE
Eur J Pharmacol; 2015 Oct; 764():30-37. PubMed ID: 26101069
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
[TBL] [Abstract][Full Text] [Related]
20. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
